Out-licensing

A new standard in drug substitution. Using new concepts & resources we are developing a medication for a population where only standard medications have been offered. Our strong opioid with anti-abuse formulation has been developed and tested in studies

Phoenux offers a new, breakthrough medication aimed for drug substitution. In Europe approx. 650,000 opioid-dependent patients are in substitution treatment, mostly using methadone and buprenorphine. Phoenux' medication is based on oral, retarded morphine, adding naloxone as anti-abuse protection, thus gaining an indication patent. Phoenux has solved the two main problems of the substitution market: high efficacy, low abuse.

Rewarding the innovative efforts of the Phoenux team, an indication patent for Europe and Eurasia has been granted. Based on this and the newly developed own formulation, the EMA has accepted the possibility for a centralized procedure. Several small Proof of Concept Studies were conducted and very successfully concluded.

Morphine as an orally taken opioid, is the closest substance nearest to the bodies` own endorphins. The new medication adds an anti abuse system based on naloxone. Oral morphine is the ideal substitution medication for opiate addicted patients. High intrinsic activity, high retention rate are associated with the medication. A small IIb trial documented the effective use of the developed medication in the population of opiate addicted patients.

Intravenous abuse of oral opioid medications has become a severe problem. Despite using naloxone as anti-abuse protection in the formulation none of the patients showed withdrawal symptoms in the oral application, this has been considered as a breakthrough. Proof of Concept Studies documented sufficient withdrawal symptoms in case of intravenous abuse to reduce the intravenous abuse potential distinctly. A sachet formulation has been developed.

Phoenux or Phoenux' partners will be required to conduct registration studies in the European market to gain registration authorization.

Phase II

The patent has been granted Worldwide but is still pending in the US.

We are interested in licensing or selling the IP for Europe and Eurasia as a whole or per country.

EP 1976 524 B1